What is Zyban? Zyban is a brand name for the drug bupropion hydrochloride.
Zyban is a prescription medication designed to help smokers quit more easily than without the drug. It comes in a pill form.
The most common side effects of ZYBAN are dry mouth and difficulty sleeping. These side effects are generally mild and often disappear after a few weeks.
Quit rates for ZYBAN were similar in patients with and without prior quit attempts using nicotine replacement therapy.
Online purchase of Zyban provides many benefits such as free medical check-ups, free shipping and deliveries, and free extra tablets.
Patients in this study were treated for 7 weeks with 1 of 3 doses of ZYBAN (100, 150, or 300 mg/day) or placebo ; quitting was defined as total abstinence during the last 4 weeks of treatment (weeks 4 through 7). Abstinence was determined by patient daily diaries and verified by carbon monoxide levels in expired air. Results of this dose-response trial with ZYBAN demonstrated a dose-dependent increase in the percentage of patients able to achieve 4-week abstinence (weeks 4 through 7). Treatment with ZYBAN at both 150 and 300 mg/day was significantly more effective than placebo in this study.
At 52 weeks, the continuous abstinence rate was 23% (95% CI 18-28) in the ZYBAN treated patients, and 28% (95% CI 23-34) for patients treated with the combination, compared with 8% (95% CI 3-12) in the placebo group. The comparisons between ZYBAN, NTS, and combination treatment in this study have not been replicated, and, therefore should not be interpreted as demonstrating the superiority of any of the active treatment arms over any other. The goal of therapy with ZYBAN is complete abstinence. If a patient has not made significant progress towards abstinence by the seventh week of therapy with ZYBAN, it is unlikely that he or she will quit during that attempt, and treatment should probably be discontinued. Patients who fail to quit smoking during an attempt may benefit from interventions to improve their chances for success on subsequent attempts. Patients who are unsuccessful should be evaluated to determine why they failed. Treatment with ZYBAN should be initiated while the patient is still smoking, since approximately 1 week of treatment is required to achieve steady-state blood levels of bupropion. Treatment with ZYBAN (7 weeks at 300 mg/day) was more effective than placebo in helping patients maintain continuous abstinence through week 26 (6 months) of the study. Patients who quit smoking while receiving ZYBAN (n 432) were then randomized to ZYBAN 300 mg/day or placebo for a total study duration of 1 year. Three patients (1.2%) treated with the combination of ZYBAN and NTS and 1 patient (0.4%) treated with NTS had study medication discontinued due to hypertension compared to none of the patients treated with ZYBAN or placebo. Selected adverse events with an incidence of at least 1% of patients treated with either ZYBAN,NTS, or the combination of ZYBAN and NTS and more frequent than in the placebo group. When patients in this study were followed out to one year, the superiority of ZYBAN and the combination of ZYBAN and NTS over placebo in helping patients to achieve abstinence from smoking was maintained. In the comparative trial, 40% of the patients treated with 300 mg/day of ZYBAN, 28% of the patients treated with 21 mg/day of NTS, and 45% of the patients treated with the combination of ZYBAN and NTS experienced insomnia compared to 18% of placebo-treated patients. Monitoring for treatment-emergent hypertension in patients treated with the combination of ZYBAN and NTS is recommended.
ZYBAN is contraindicated in patients treated with WELLBUTRIN (bupropion hydrochloride), the immediate-release formulation; WELLBUTRIN SR (bupropion hydrochloride), the sustained-release formulation; WELLBUTRIN XL (bupropion hydrochloride), the extended-release formulation; or any other medications that contain bupropion because the incidence of seizure is dose dependent. Patients should be made aware that ZYBAN contains the same active ingredient found in WELLBUTRIN, WELLBUTRIN SR, and WELLBUTRIN XL used to treat depression, and that ZYBAN should not be used in combination with WELLBUTRIN (bupropion hydrochloride), the immediate release formulation; WELLBUTRIN SR (bupropion hydrochloride), the sustained-release formulation; WELLBUTRIN XL (bupropion hydrochloride), the extended-release formulation; or any other medications that contain bupropion.
Adverse events for which frequencies are not provided occurred in clinical trials or postmarketing experience with bupropion. Only those adverse events not previously listed for sustained-release bupropion are included. The extent to which these events may be associated with ZYBAN is unknown.
Hepatic Impairment: ZYBAN should be used with extreme caution in patients with severe hepatic cirrhosis. In these patients a reduced frequency of dosing is required, as peak bupropion levels are substantially increased and accumulation is likely to occur in such patients to a greater extent than usual. The dose should not exceed 150 mg every other day in these patients (see CLINICAL PHARMACOLOGY, PRECAUTIONS, and DOSAGE AND ADMINISTRATION DOSAGE AND ADMINISTRATION DOSAGE AND ADMINISTRATION DOSAGE AND ADMINISTRATION ). ZYBAN should be used with caution in patients with hepatic impairment (including mild to moderate hepatic cirrhosis) and a reduced frequency of dosing should be considered in patients with mild to moderate hepatic cirrhosis (see CLINICAL PHARMACOLOGY CLINICAL PHARMACOLOGY CLINICAL PHARMACOLOGY, WARNINGS, and PRECAUTIONS ). Dosage Adjustment for Patients with Impaired Renal Function: ZYBAN should be used with caution in patients with renal impairment and a reduced frequency of dosing should be considered (see CLINICAL PHARMACOLOGY CLINICAL PHARMACOLOGY CLINICAL PHARMACOLOGY and PRECAUTIONS ). Bupropion is extensively metabolized in the liver to active metabolites, which are further metabolized and subsequently excreted by the kidneys. ZYBAN should be used with caution in patients with renal impairment and a reduced frequency of dosing should be considered as bupropion and the metabolites of bupropion may accumulate in such patients to a greater extent than usual. Hepatic Impairment: ZYBAN should be used with extreme caution in patients with severe hepatic cirrhosis. In these patients, a reduced frequency of dosing is required. ZYBAN should be used with caution in patients with hepatic impairment (including mild to moderate hepatic cirrhosis) and reduced frequency of dosing should be considered in patients with mild to moderate hepatic cirrhosis.
There is no clinical experience establishing the safety of ZYBAN in patients with a recent history of myocardial infarction or unstable heart disease. Therefore, care should be exercised if it is used in these groups. The risk of seizures is also related to patient factors, clinical situation, and concomitant medications, which must be considered in selection of patients for therapy with ZYBAN. ZYBAN should be discontinued and not restarted in patients who experience a seizure while on treatment. Treatment with ZYBAN should be continued for 7 to 12 weeks; longer treatment should be guided by the relative benefits and risks for individual patients. If a patient has not made significant progress towards abstinence by the seventh week of therapy with ZYBAN, it is unlikely that he or she will quit during that attempt, and treatment should probably be discontinued. NTS 21 mg/day was added to treatment with ZYBAN after approximately 1 week when the patient reached the target quit date. Patients should set a ‘target quit date’ within the first 2 weeks of treatment with ZYBAN, generally in the second week. Whether to continue treatment with ZYBAN for periods longer than 12 weeks for smoking cessation must be determined for individual patients. Although ZYBAN is not a treatment for depression, it contains the same active ingredient as the antidepressant medications WELLBUTRIN’, WELLBUTRIN SR’, and WELLBUTRIN XL’. This section of the Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines.
Treatment with ZYBAN was initiated at 150 mg/day for 3 days while the patient was still smoking and increased to 150 mg twice daily for the remaining treatment period. Adverse Events Associated With the Discontinuation of Treatment: Adverse events were sufficiently troublesome to cause discontinuation of treatment in 8% of the 706 patients treated with ZYBAN and 5% of the 313 patients treated with placebo. Symptoms were sufficiently severe to require discontinuation of treatment in 0.6% of patients treated with ZYBAN and none of the patients treated with placebo. The continuous abstinence rate was 30% (95% CI 24-35) in the ZYBAN treated patients, and 33% (95% CI 27-39) for patients treated with the combination at 26 weeks compared with 13% (95% CI 7-18) in the placebo group. Patients aged 36 to 76 years were randomized to ZYBAN 300 mg/day (n 204) or placebo (n 200) and treated for 12 weeks. The third study was a long-term maintenance trial conducted at 5 clinical centers. Patients in this study received open-label ZYBAN 300 mg/day for 7 weeks. Abstinence from smoking was determined by patient self-report and verified by expired air carbon monoxide levels. This trial demonstrated that at 6 months, continuous abstinence rates were significantly higher for patients continuing to receive ZYBAN than for those switched to placebo (p< 0.05; 55% versus 44%). Treatment with ZYBAN (150 or 300 mg/day) was more effective than placebo in helping patients achieve 4-week abstinence. Four treatments were evaluated: ZYBAN 300 mg/day, nicotine transdermal system (NTS) 21 mg/day, combination of ZYBAN 300 mg/day plus NTS 21 mg/day, and placebo. Combination Treatment With ZYBAN and a Nicotine Transdermal System (NTS): Combination treatment with ZYBAN and NTS may be prescribed for smoking cessation. The prescriber should review the complete prescribing information for both ZYBAN and NTS before using combination treatment.
Quit rates for ZYBAN were similar in patients with and without prior quit attempts using nicotine replacement therapy. Administration of ZYBAN to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and gradual dose increases. The chance of having seizures increases with higher doses of ZYBAN. For more information, see the sections ‘Who should not take ZYBAN?’ and ‘What should I tell my doctor before using ZYBAN?’ Tell your doctor about all of your medical conditions and all the medicines you take. Do not take any other medicines while you are using ZYBAN unless your doctor has said it is okay to take them. Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Many medicines increase your chances of getting seizures or other serious side effects if you take them while you are using ZYBAN. Tell your doctor if you are planning to use nicotine replacement therapy because your doctor will probably want to check your blood pressure regularly to make sure that it stays within acceptable levels. DO NOT SMOKE AT ANY TIME if you are using a nicotine patch or any other nicotine product along with ZYBAN. It is possible to get too much nicotine and have serious side effects. ZYBAN and nicotine patches can be used at the same time but should only be used together under the supervision of your doctor. ZYBAN is chemically unrelated to nicotine or other agents currently used in the treatment of nicotine addiction. Depending on the study and the measure used, treatment with ZYBAN showed evidence of reduction in craving for cigarettes or urge to smoke compared to placebo. Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with ZYBAN. The consumption of alcohol during treatment with ZYBAN should be minimized or avoided (also see CONTRAINDICATIONS ). Symptoms were sufficiently severe to require discontinuation of treatment in 0.8% of patients treated with ZYBAN and none of the patients in the other 3 treatment groups. Selected adverse events with an incidence of at least 1% of patients treated with ZYBAN and more frequent than in the placebo group. ZYBAN is contraindicated in patients who have shown an allergic response to bupropion or the other ingredients that make up ZYBAN. The mechanism by which ZYBAN enhances the ability of patients to abstain from smoking is unknown. It is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms. ZYBAN should be used with a patient support program. It is important to participate in the behavioral program, counseling, or other support program your health care professional recommends. Prescriptions for ZYBAN should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose. Use In Patients With Chronic Obstructive Pulmonary Disease ( COPD ): ZYBAN was evaluated in a randomized, double-blind, comparative study of 404 patients with mild-to-moderate COPD, defined as FEV 1 ≥ 35%, FEV 1 /FVC≤ 70% and a diagnosis of chronic bronchitis, emphysema and/or small airways disease. ZYBAN is contraindicated in patients undergoing abrupt discontinuation of alcohol or sedatives (including benzodiazepines ).
General: Allergic Reactions: Anaphylactoid/anaphylactic reactions characterized by symptoms such as pruritus, urticaria, angioedema, and dyspnea requiring medical treatment have been reported at a rate of about 1 to 3 per thousand in clinical trials of ZYBAN. In addition, there have been rare spontaneous postmarketing reports of erythema multiforme, Stevens-Johnson syndrome, and anaphylactic shock associated with bupropion. Smoking Cessation: Physiological changes resulting from smoking cessation itself, with or without treatment with ZYBAN, may alter the pharmacokinetics of some concomitant medications, which may require dosage adjustment. Blood concentrations of concomitant medications that are extensively metabolized, such as theophylline and warfarin, may be expected to increase following smoking cessation due to de-induction of hepatic enzymes. ZYBAN (bupropion hydrochloride) Sustained-Release Tablets are a non-nicotine aid to smoking cessation. ZYBAN Sustained-Release Tablets, 150 mg of bupropion hydrochloride, are purple, round, biconvex, film-coated tablets printed with ‘ZYBAN 150′ in bottles of 60 (NDC 0173-0556-02) tablets and the ZYBAN Advantage Pack’ containing 1 bottle of 60 (NDC 0173-0556-01) tablets. Absorption: Bupropion has not been administered intravenously to humans; therefore, the absolute bioavailability of ZYBAN Sustained-Release Tablets in humans has not been determined.
Following oral administration of two 150-mg ZYBAN tablets with and without 800 mg of cimetidine, the pharmacokinetics of bupropion and its hydroxy metabolite were unaffected. Following oral administration of ZYBAN to healthy volunteers, peak plasma concentrations of bupropion are achieved within 3 hours.
Drugs that Lower Seizure Threshold: Concurrent administration of ZYBAN and agents (e.g., antipsychotics, antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution (see WARNINGS ). Few systemic data have been collected on the metabolism of ZYBAN following concomitant administration with other drugs or, alternatively, the effect of concomitant administration of ZYBAN on the metabolism of other drugs. The concurrent administration of ZYBAN and a monoamine oxidase (MAO) inhibitor is contraindicated. At least 14 days should elapse between discontinuation of an MAO inhibitor and initiation of treatment with ZYBAN. The more common events leading to discontinuation of treatment with ZYBAN included nervous system disturbances (3.4%), primarily tremors, and skin disorders (2.4%), primarily rashes. Systematic evaluation of ZYBAN 300 mg/day for maintenance therapy demonstrated that treatment for up to 6 months was efficacious. Usual Dosage for Adults: The recommended and maximum dose of ZYBAN is 300 mg/day, given as 150 mg twice daily. Insomnia may be minimized by avoiding bedtime doses and, if necessary, reduction in dose. Psychosis, Confusion, and Other Neuropsychiatric Phenomena: In clinical trials with ZYBAN conducted in nondepressed smokers, the incidence of neuropsychiatric side effects was generally comparable to placebo. Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of ZYBAN or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Initially developed and marketed as an antidepressant (WELLBUTRIN Tablets and WELLBUTRIN SR Sustained-Release Tablets), ZYBAN is also chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. It is (’)-1-(3-chlorophenyl)-2- -1-propanone hydrochloride. ZYBAN Tablets are supplied for oral administration as 150-mg (purple), film-coated, sustained-release tablets. Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 6 hours after administration of ZYBAN Tablets.
The efficacy of ZYBAN as an aid to smoking cessation was demonstrated in 3 placebo-controlled, double-blind trials in nondepressed chronic cigarette smokers (n 1,940, ≥ 15 cigarettes per day). In these studies, ZYBAN was used in conjunction with individual smoking cessation counseling. Most people should take ZYBAN for at least 7 to 12 weeks. Some people may need to take ZYBAN for a longer period of time to assist in their smoking cessation efforts. ZYBAN combined with a behavior modification program has been shown to help people with COPD quit smoking. It is important to participate in the behavior program, counseling, or other support program your health care professional recommends. Studies have shown that more than one third of people quit smoking for at least 1 month while taking ZYBAN and participating in a patient support program. Some patients get high blood pressure, sometimes severe, while taking ZYBAN. The chance of high blood pressure may be increased if you also use nicotine replacement therapy (for example, a nicotine patch) to help you stop smoking (see ‘Can ZYBAN be used at the same time as nicotine patches?’). Some patients get seizures while taking ZYBAN. If you have a seizure while taking ZYBAN, stop taking the tablets and call your doctor right away. A patient should stop taking ZYBAN and consult a doctor if experiencing allergic or anaphylactoid/anaphylactic reactions (e.g., skin rash, pruritus, hives, chest pain, edema, and shortness of breath) during treatment. Some patients have unusual thoughts or behaviors while taking ZYBAN, including delusions (believe you are someone else), hallucinations (seeing or hearing things that are not there), paranoia (feeling that people are against you), or feeling confused. If this happens to you, call your doctor.
Keep ZYBAN out of the reach of children. This Medication Guide summarizes important information about ZYBAN. For more information, talk with your doctor. If you have any questions about ZYBAN, ask your doctor or pharmacist. IMPORTANT: Be sure to read both sections of this Medication Guide. General Information about ZYBAN. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not take any other medicines while using ZYBAN unless your doctor has told you it is okay. You can ask your doctor or pharmacist for information about ZYBAN that is written for health professionals. Tell your doctor about your medical conditions. It is not known if ZYBAN can harm your unborn baby. Tell your doctor right away about any side effects that bother you. These are not all the side effects of ZYBAN. For a complete list, ask your doctor or pharmacist. The most common side effects of ZYBAN are dry mouth and difficulty sleeping. These side effects are generally mild and often disappear after a few weeks. Follow your doctor’s instructions. It takes about 1 week for ZYBAN to reach the right levels in your body to be effective.
In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by the CYP2B6 isoenzyme. Therefore, the potential exists for a drug interaction between ZYBAN and drugs that are substrates or inhibitors of the CYP2B6 isoenzyme (e.g., orphenadrine, thiotepa, and cyclophosphamide). To monitor fetal outcomes of pregnant women exposed to ZYBAN, GlaxoSmithKline maintains a Bupropion Pregnancy Registry.
Because of the potential for serious adverse reactions in nursing infants from ZYBAN, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. ZYBAN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Due to the dose-related risk of seizures with ZYBAN, hospitalization following suspected overdose should be considered.
Using ZYBAN and nicotine patches together may raise your blood pressure, sometimes severely. Do not drive a car or use heavy machinery until you know how ZYBAN affects you. ZYBAN can impair your ability to perform these tasks. ZYBAN has not been studied in children under the age of 18 and is not approved for use in children and teenagers.
Labor and Delivery: The effect of ZYBAN on labor and delivery in humans is unknown. Following chronic dosing of 150 mg of ZYBAN every 12 hours for 14 days (n 34), the mean Cl/F at steady state was 160 L/hr (±23%). There were no reports of activation of psychosis or mania in clinical trials with ZYBAN conducted in nondepressed smokers.
You should set a date to stop smoking during the second week you’re taking ZYBAN. It is not physically dangerous to smoke and use ZYBAN at the same time. To maximize your chance of quitting, you should not stop smoking until you have been taking ZYBAN for 1 week.
Do not change your dose or stop taking ZYBAN without talking with your doctor first. Severe allergic reactions: Stop taking ZYBAN and call your doctor right away if you get a rash, itching, hives, fever, swollen lymph glands, painful sores in the mouth or around the eyes, swelling of the lips or tongue, chest pain, or have trouble breathing. These could be signs of a serious allergic reaction. Do not drink a lot of alcohol while taking ZYBAN. If you usually drink a lot of alcohol, talk with your doctor before suddenly stopping. If you can use ZYBAN while you are pregnant, talk to your doctor about how you can be on the Bupropion Pregnancy Registry. Do not use ZYBAN for a condition for which it was not prescribed. Do not give ZYBAN to other people, even if they have the same symptoms you have. It may harm them.
Hepatic Impairment: ZYBAN should be used with extreme caution in patients with severe hepatic cirrhosis. In these patients a reduced frequency of dosing is required, as peak bupropion levels are substantially increased and accumulation is likely to occur in such patients to a greater extent than usual. The dose should not exceed 150 mg every other day in these patients (see CLINICAL PHARMACOLOGY, PRECAUTIONS, and DOSAGE AND ADMINISTRATION). ZYBAN is contraindicated in patients treated with WELLBUTRIN, WELLBUTRIN SR, or any other medications that contain bupropion because the incidence of seizure is dose dependent. WARNINGS Patients should be made aware that ZYBAN contains the same active ingredient found in WELLBUTRIN and WELLBUTRIN SR used to treat depression, and that ZYBAN should not be used in combination with WELLBUTRIN, WELLBUTRIN SR, or any other medications that contain bupropion.
The concurrent administration of ZYBAN and a monoamine oxidase (MAO) inhibitor is contraindicated. At least 14 days should elapse between discontinuation of an MAO inhibitor and initiation of treatment with ZYBAN. ZYBAN is contraindicated in patients who have shown an allergic response to bupropion or the other ingredients that make up ZYBAN. The risk of seizures is also related to patient factors, clinical situation, and concurrent medications, which must be considered in selection of patients for therapy with ZYBAN. ZYBAN should be discontinued and not restarted in patients who experience a seizure while on treatment ZYBAN is contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa because of a higher incidence of seizures noted in patients treated for bulimia with the immediate-release formulation of bupropion. ZYBAN should be administered with extreme caution to patients with a history of seizure, cranial trauma, or other predisposition(s) toward seizure, or patients treated with other agents (e.g., antipsychotics, antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold. CONTRAINDICATIONS ZYBAN is contraindicated in patients with a seizure disorder. ZYBAN is contraindicated in patients undergoing abrupt discontinuation of alcohol or sedatives (including benzodiazepines).
Depending on the study and the measure used, treatment with ZYBAN showed evidence of reduction in craving for cigarettes or urge to smoke compared to placebo.” According to the results reported during clinical trials, “treatment with ZYBAN reduced withdrawal symptoms compared to placebo. Zyban has proven more effective than placebo in clinical testing, with success rates ranging as high as 58% in one study. Zyban is a prescription medication designed to help smokers quit more easily than without the drug. It comes in a pill form. With Zyban, you continue to smoke when you first start taking the medication, eventually reaching a quit-date, and taking the drug for a period of time after quitting. GlaxoSmithKline “repackaged” Wellbutrin and marketed it as the smoking-cessation drug Zyban.
There is a risk of seizure associated with ZYBAN, which is increased in certain patients.” There are other risks associated with the use of ZYBAN, so it is important to talk to your healthcare professional to see whether ZYBAN is right for you.
Unlike nicotine patches or nicotine gum, Zyban does not put more nicotine into your body. According the the Zyban website, “The most common side effects experienced with ZYBAN include dry mouth and difficulty sleeping.
In 1997, bupropion was approved by the FDA for use as a smoking cessation aid under the name Zyban.
The MHRA received 60 reports of ” suspected adverse reactions to Zyban which had a fatal outcome”. If you drink alcohol regularly, talk with your doctor before changing the amount you drink. Zyban can cause seizures in people who drink a lot of alcohol and then suddenly quit drinking when they start using the medication. Do not take Zyban if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl), or tranylcypromine (Parnate) in the last 14 days.
Zyban may cause seizures, especially in people with certain medical conditions or when using certain drugs.
In a trial of people who didn’t want to stop smoking, Zyban was no more effective than placebo 2. Set a date to quit smoking during the second week of Zyban treatment. By that time you will have enough of the medicine in your blood stream to help you quit smoking. If you take Zyban to help you stop smoking, you may continue to smoke for about 1 week after you start the medicine.
If you take Wellbutrin for depression, do not also take Zyban to quit smoking. Zyban approximately doubles the chances of quitting smoking at 3 months from quit date 3. This drops back a little at 1 year from stopping. Zyban has an antidepressant action. Its effect on quitting smoking may not be directly related to its antidepressant effects 2. Initially developed and marketed as an antidepressant ( WELLBUTRIN Tablets and WELLBUTRIN SR Sustained-Release Tablets), Zyban is also chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. It is (±)-1-(3-chlorophenyl)-2- -1-propanone hydrochloride. Zyban ( bupropion hydrochloride ) Sustained-Release Tablets are a non-nicotine aid to smoking cessation. In 1997, bupropion was approved by the FDA for use as a smoking cessation aid under the name Zyban. Bupropion is available with a prescription under the brand names Wellbutrin, Wellbutrin SR, Wellbutrin XL, and Zyban. Other brand or generic formulations may also be available. Do not crush, chew, or break the extended-release tablet (Wellbutrin SR, Wellbutrin XL, Zyban SR). Talk to your doctor if you are having trouble quitting after you have used Zyban for at least 7 weeks. Using nicotine with Zyban may raise your blood pressure and your doctor may want to check your blood pressure regularly. Do not smoke at any time if you are using a nicotine product along with Zyban.
Zyban may reduce weight gain from stopping smoking, while it is being taken, although weight gain can occur when Zyban is stopped 4. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. Do not take Zyban if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl), or tranylcypromine (Parnate) in the last 14 days. Do not give Zyban to anyone younger than 18 years old without the advice of a doctor. Do not take Zyban without telling your doctor if you are breast-feeding a baby.
Symptoms of a Zyban overdose may include seizures, muscle stiffness, hallucinations, fainting, fast or uneven heartbeat, shallow breathing, heart failure, or coma. Your pharmacist has information about Zyban written for health professionals that you may read.
Zyban is started before quitting smoking, with a target date usually in the second week of taking Zyban 1. If you have any of these conditions, you may not be able to use Zyban, or you may need a dosage adjustment or special tests during treatment.
It is suggested for individuals who desire to quit from their smoking habit. Online purchase of Zyban provides many benefits such as free medical check-ups, free shipping and deliveries, and free extra tablets.
You can now proceed to order Zyban online after securing a prescription from an online doctor. If you want to buy Zyban form internet drugstores, consult your doctor first.
Zyban is also effective in aiding you fight syndromes connected with nicotine withdrawal. The lowest prices for Zyban can also be found in online pharmacies. It is no wonder that many people are buying Zyban from professional and licensed online pharmacies. You need to have a credit card to place your order and pay for it. After doing all these, just wait and relax because your Zyban medicine will be delivered to your home after 1 to 3 days. You can totally stop smoking two weeks after medication with Zyban. Zyban also does not have nicotine in its ingredients. It would not be complicated to stop taking Zyban because you will not suffer from nicotine withdrawal.
It has been shown to dramatically reduce nicotine withdrawal symptoms. What is Zyban? Zyban is a brand name for the drug bupropion hydrochloride. What are the Side Effects of Using Zyban? Like many drugs, bupropion hydrocholoride, commonly known as Zyban does have side effects. Learn what they are and how this drug could affect you.
Wellbutrin SR and Wellbutrin XL are typically used to treat depression, while Zyban is most often prescribed as a quit smoking aid. Can I Use NRT’s with Zyban? Zyban used in conjunction with a NRT can be a good choice for people who have a lot of trouble with nicotine withdrawal.
How Do I Use Zyban? Information about how to use Zyban to help you quit smoking. How does Zyban Work? While it isn’t understood exactly how bupropion(Zyban) works, we do know that this prescription-strength medicine alters the brain’s chemistry.